Skip to content

MAZE MAZE Return on equity

Return on equity at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
24.2%
Septerna, Inc. logo
Septerna, Inc.SEPN
-12.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-45.6%-66.1pp
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-42.9%+1.3pp
Zymeworks logo
ZymeworksZYME
-42%+29.2pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-61.4%-2.5pp

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Calculated from MAZE’s reported figures.

Based on trailing twelve months.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's return on equity?
MAZE (MAZE) reported return on equity of -38.7% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.